Back to results
US 10,245,178 B1Granted
Anterior chamber drug-eluting ocular implant
AssigneeGlaukos Corporation
InventorsHarold Heitzmann, Vanessa Tasso
Life of this patent
Estimating the term…
Abstract
Disclosed herein are drug delivery ocular implants comprising an elongate outer shell having a proximal end, and distal end and being shaped to define an interior lumen, at least one therepautic agent positioned within the lumen, wherein the outer shell has at least a first thickness, the outer shell comprises one or more regions of drug release, and the implant is dimensioned for implantation within the anterior chamber of the eye.
Claims32
A drug delivery ocular implant comprising:
- an elongate outer shell having a proximal end, and a distal end, and being shaped to define an interior space;
- at least one drug positioned within said interior space;
- wherein said outer shell has at least a first thickness and an outer diameter;
- wherein said outer shell comprises one or more regions of drug release;
- wherein said implant is shaped and sized so as to be suitable for implantation within an anterior chamber of an eye;
- wherein said implant is shaped and sized to be positioned fully in an irido-corneal angle of the anterior chamber of the eye;
- wherein said implant is configured without one or more anchoring protrusions, wherein the outer shell provides sufficient friction against tissue of the irido-corneal angle to hold the implant in position in the irido-corneal angle;
- and
- wherein said implant is configured to be deformed from a straightened to an arcuate shape for retention within the irido-corneal angle.
6 more elements
A drug delivery ocular implant comprising:
- an elongate polymeric body comprising an outer shell having a proximal end, and a distal end and being shaped to define an interior space;
- at least one drug positioned within said interior space;
- wherein said outer shell has at least a first thickness and an outer diameter;
- wherein said outer shell comprises one or more regions of drug release;
- wherein said implant is shaped and sized so as to be suitable for implantation within an anterior chamber of an eye;
- wherein said implant is shaped and sized to be positioned fully in an irido-corneal angle of the anterior chamber of the eye and fully within the anterior chamber of the eye;
- wherein said implant is configured with one or more anchoring protrusions, wherein the one or more anchoring protrusions hold the implant in position in the irido-corneal angle;
- and
- wherein said implant is configured to be deformed from a straightened to an arcuate shape for retention within the irido-corneal angle.
6 more elements
A drug delivery ocular implant comprising:
- an elongate polymeric body comprising a proximal end and a distal end, a polymer, and at least one drug blended with the polymer of the elongate polymeric body;
- wherein said elongate polymeric body is biodegradable;
- wherein the at least one drug comprises one or more of travoprost or dexamethasone;
- wherein said implant is shaped and sized so as to be suitable for implantation within an anterior chamber of an eye;
- wherein said implant is shaped and sized to be positioned fully in an irido-corneal angle and fully within the anterior chamber of the eye;
- wherein said polymeric body provides sufficient friction against tissue of the irido-corneal angle to hold the implant in position in the irido-corneal angle;
- and
- wherein said implant is configured to be deformed from a straightened to an arcuate shape for retention within the irido-corneal angle.
5 more elements
Dependencies are inferred from the claim text.